All In Biotech

NDA 021829 · Ucb INC

Neupro

Rotigotine · Transdermal · Nonergot Dopamine Agonist

Novel

Last checked: Nov 20, 2026Latest source record: Jul 12, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 9, 2007

Approved uses

3

Original approval plus efficacy supplements

Registered trials

95

34 Phase 3, 2 recruiting

FAERS reports

14,738

9,295 serious, 2,175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2026.

NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 ) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.

Mechanism: Rotigotine is a non-ergoline dopamine agonist. The precise mechanism of action of rotigotine as a treatment for Parkinson's disease is unknown, although it is thought to be related to its ability to stimulate dopamine receptors within the caudate-putamen in the brain. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • NEUPRO · ROTIGOTINE 1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NEUPRO · ROTIGOTINE 4MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NEUPRO · ROTIGOTINE 3MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NEUPRO · ROTIGOTINE 6MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NEUPRO · ROTIGOTINE 2MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
  • NEUPRO · ROTIGOTINE 8MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rotigotine" as an intervention, any sponsor and status, largest first.

All 95 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product adhesion issue1,963
  • drug ineffective1,171
  • fall1,013
  • death984
  • off label use922
  • parkinson^s disease800
  • hallucination771
  • dyskinesia698
  • tremor655
  • nausea555
  • dizziness523
  • somnolence477

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2007128
2008603
2009126
2010131
2011129
2012170
2013260
2014302
2015471
2016820
2017917
2018866
20191,295
20201,207
20211,579
20221,461
20231,098
20241,164
20251,075
2026936

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neupro (Rotigotine)

2024 spending

$90.1M

Beneficiaries

14,920

77,655 claims

Per beneficiary

$6,037

$27.60 per unit

View as table
YearSpending
2020$95,138,638
2021$94,625,403
2022$96,535,024
2023$92,722,198
2024$90,068,151

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 133 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.